Archer Investment Corp Acquires Shares of 6,546 Oruka Therapeutics, Inc. $ORKA

Posted by Geri Gentry on Jul 15th, 2026

Archer Investment Corp acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) during the 1st quarter, Holdings Channel.com reports. The fund acquired 6,546 shares of the company’s stock, valued at approximately $321,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Kennedy Capital Management LLC lifted its position in Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. boosted its holdings in Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics during the 4th quarter worth about $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ORKA. Barclays lifted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Weiss Ratings downgraded Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wedbush set a $165.00 target price on Oruka Therapeutics in a report on Monday, April 27th. Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the company a “buy” rating in a research report on Monday, April 27th. Finally, Leerink Partners set a $120.00 price target on Oruka Therapeutics in a report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $134.30.

Check Out Our Latest Analysis on Oruka Therapeutics

Oruka Therapeutics Trading Up 3.4%

NASDAQ ORKA opened at $87.47 on Wednesday. The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of -45.09 and a beta of -0.35. The stock has a 50-day moving average of $71.24 and a 200 day moving average of $52.26. Oruka Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $97.78.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. Equities analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total value of $6,191,850.00. Following the sale, the director owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. This trade represents a 58.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the sale, the senior vice president directly owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. The trade was a 38.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 188,406 shares of company stock worth $12,019,683. Corporate insiders own 23.49% of the company’s stock.

Oruka Therapeutics Profile

(Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.